Wasatch Advisors Inc Kymera Therapeutics, Inc. Transaction History

Wasatch Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$13.9 - $23.88 $8.71 Million - $15 Million	-626,443 Reduced 52.23%	572,907 $7.96 Million
Q2 2023 Aug 07, 2023	BUY	$22.4 - $34.92 $3.63 Million - $5.65 Million	161,936 Added 15.61%	1,199,350 $27.6 Million
Q1 2023 May 12, 2023	BUY	$24.84 - $38.75 $5.1 Million - $7.95 Million	205,193 Added 24.66%	1,037,414 $30.7 Million
Q4 2022 Feb 14, 2023	SELL	$19.57 - $30.92 $4.47 Million - $7.06 Million	-228,340 Reduced 21.53%	832,221 $20.8 Million
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $10.2 Million - $16.8 Million	489,917 Added 85.85%	1,060,561 $23.1 Million
Q2 2022 Aug 12, 2022	BUY	$14.13 - $42.55 $4.71 Million - $14.2 Million	333,287 Added 140.42%	570,644 $11.2 Million
Q1 2022 May 13, 2022	SELL	$35.3 - $64.68 $126,868 - $232,459	-3,594 Reduced 1.49%	237,357 $10 Million
Q4 2021 Feb 15, 2022	SELL	$49.91 - $65.56 $20,712 - $27,207	-415 Reduced 0.17%	240,951 $15.3 Million
Q3 2021 Nov 12, 2021	BUY	$47.8 - $66.66 $108,219 - $150,918	2,264 Added 0.95%	241,366 $14.2 Million
Q2 2021 Aug 12, 2021	BUY	$31.08 - $51.95 $7.43 Million - $12.4 Million	239,102 New	239,102 $11.6 Million

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.